Many treatments for Alzheimer’s disease have been shown to be safe and to have some positive effect when tested in animal models of Alzheimer’s disease. However, many of these potentially successful drugs have not been brought to human trials because of the increased cost and risk at this stage of research.
The Alzheimer's Drug Discovery Foundation is responding to this problem with the Alzheimer’s Program to Accelerate Clinical Trials. The goal of the program is to increase the number of innovative drugs tested in humans for Alzheimer’s disease.
To that end, grants of up to $3 million will be awarded for biomarker-based pilot clinical trials. Priority areas include repurposing (testing drugs approved for other indications in Alzheimer's disease clinical trials) and novel therapies supported by preclinical in vivo data linking the therapeutic approach to Alzheimer’s disease or related dementias.
Applications may be submitted by nonprofit academic institutions and for-profit biotechnology companies, both public and private, worldwide.
Letters of Intent must be received no later than November 17, 2017. Upon review, selected applicants will be invited to submit a full application by December 8, 2017.
See the ADDF website for a complete program description, eligibility criteria, and application guidelines.